STOCK TITAN

Sunshine Biopharma (SBFM) investors cap warrant-driven stake at 9.99%

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Sunshine Biopharma Inc. received an updated Schedule 13G/A from Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC reporting their beneficial ownership in the company’s common stock. As of June 30, 2026, they may be deemed to beneficially own 235,697 shares of common stock issuable upon exercise of a warrant, representing 9.99% of the outstanding common stock. This percentage is calculated using 2,123,635 shares outstanding as of May 28, 2026 plus the 235,697 warrant shares. Additional warrant shares are contractually blocked from exercise above ownership caps of 9.99% for one warrant and 4.99% for another, which limits the reportable beneficial ownership.

Positive

  • None.

Negative

  • None.
Beneficially owned shares 235,697 shares Shares of common stock issuable upon exercise of Intracoastal Warrant 1
Percent of class 9.99% Beneficial ownership percentage of Sunshine Biopharma common stock
Shares outstanding baseline 2,123,635 shares Common stock outstanding as of May 28, 2026 used in ownership calculation
Additional Warrant 1 shares excluded 1,861,624 shares Shares from Intracoastal Warrant 1 excluded due to 9.99% blocker provision
Additional Warrant 2 shares excluded 100,000 shares Shares from Intracoastal Warrant 2 excluded due to 4.99% blocker provision
Total potential shares without blockers 2,197,321 shares Potential beneficial ownership if blocker provisions did not apply
beneficial ownership financial
"each of the Reporting Persons may have been deemed to have beneficial ownership of 235,697 shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
blocker provision financial
"Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise"
warrant financial
"shares of Common Stock issuable upon exercise of a warrant held by Intracoastal"
A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.
CUSIP No. financial
"CUSIP No.: 867781809"
limited liability company financial
"Intracoastal Capital LLC, a Delaware limited liability company"
A limited liability company (LLC) is a business structure that separates the owners’ personal assets from the company’s debts and legal obligations, like a protective shield that keeps personal savings and property distinct from business risk. For investors, that protection reduces personal financial exposure and often brings flexible rules for profit sharing and taxes, but it can also affect how easily interests are bought or sold and how decisions are made.

FAQ

What ownership stake in Sunshine Biopharma (SBFM) do the reporting persons disclose?

The reporting persons disclose beneficial ownership of 235,697 shares of Sunshine Biopharma common stock, representing 9.99% of the class, based on 2,123,635 shares outstanding plus the warrant shares included in the calculation.

Who are the reporting persons on this Sunshine Biopharma (SBFM) Schedule 13G/A?

The Schedule 13G/A is filed jointly by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC. Kopin and Asher are individuals in the United States, and Intracoastal is a Delaware limited liability company.

How is the 9.99% beneficial ownership in SBFM calculated?

The 9.99% beneficial ownership is based on 2,123,635 Sunshine Biopharma shares outstanding as of May 28, 2026, plus 235,697 shares of common stock issuable upon exercise of a warrant held by Intracoastal included in the ownership.

What blocker provisions limit the reporting persons’ ownership in Sunshine Biopharma (SBFM)?

One Intracoastal warrant has a 9.99% blocker, and a second warrant has a 4.99% blocker. These provisions prevent exercises that would push beneficial ownership above those percentages, so excluded shares are not counted in the reported position.

How many additional SBFM shares are tied to the Intracoastal warrants but excluded by blockers?

The filing notes 1,861,624 additional shares from Intracoastal Warrant 1 and 100,000 from Intracoastal Warrant 2 are excluded due to blocker provisions, even though they are issuable upon exercise of those warrants.

What would the reporting persons’ SBFM beneficial ownership be without blocker provisions?

Without the blocker provisions, the reporting persons may have been deemed to beneficially own 2,197,321 shares of Sunshine Biopharma common stock, reflecting all shares issuable under the referenced Intracoastal warrants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





867781809

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Mitchell P. Kopin
Signature:/s/ Mitchell P. Kopin
Name/Title:Mitchell P. Kopin
Date:08/13/2026
Daniel B. Asher
Signature:/s/ Daniel B. Asher
Name/Title:Daniel B. Asher
Date:08/13/2026
Intracoastal Capital LLC
Signature:/s/ Mitchell P. Kopin
Name/Title:Mitchell P. Kopin, Manager
Date:08/13/2026